Guest col­umn: What hap­pened with Es­pe­ri­on — and what de­fines suc­cess or fail­ure?

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

On April 1, End­points News ed­i­tor-in-chief and founder John Car­roll is­sued an open of­fer to biotech start­up ex­ecs/VCs of failed biotechs to de­tail what hap­pened, what mov­ing on looks like, and ex­plain­ing fail­ure. This is the first guest col­umn pub­lished in re­sponse to that of­fer, from Tim Mayleben. Mayleben stepped down as CEO of Es­pe­ri­on Ther­a­peu­tics a lit­tle less than a year ago af­ter a Q1 mis­fire on the num­bers raised fresh doubts about the fu­ture of their cho­les­terol drug be­mpe­doic acid. Over the past year, its stock has plunged 78% dur­ing a bear mar­ket for biotech stocks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER